Hanmi Science Co., Ltd. (KRX:008930)

Market Cap	2.60T +32.9%
Revenue (ttm)	1.34T -0.1%
Net Income	75.14B -28.4%
EPS	1,110.10 -28.3%
Shares Out	67.71M
PE Ratio	34.59
Forward PE	n/a
Dividend	400.00 (1.05%)
Ex-Dividend Date	Mar 30, 2026

Volume	25,629
Average Volume	499,845
Open	37,600
Previous Close	38,400
Day's Range	37,100 - 37,600
52-Week Range	24,250 - 55,500
Beta	0.65
RSI	46.09
Earnings Date	Feb 5, 2026

About Hanmi Science

Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer, as well as children's and adult’s bowel preparation and cold medicines, and cephalosporin antibiotics. The company also offers general foods, health functional foods, soy milk, and medical equipment. In addition, it offers automated drug management systems. The company sells its products through online and offline pharmacies. The company was formerly known as ...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 1973
• Employees: 476
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 008930

Financial Performance

In 2024, Hanmi Science's revenue was 1.28 trillion, an increase of 2.85% compared to the previous year's 1.25 trillion. Earnings were 59.42 billion, a decrease of -48.38%.